Compare Intuitive Surgical, Inc. (ISRG) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Nuwellis Inc — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Intuitive Surgical, Inc. is far larger — about 66709.1× Nuwellis Inc's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Nuwellis Inc for 26 Days on average.
| ISRG | NUWE | |
|---|---|---|
Market Cap | $146.76B | $2.20M |
Volume | 2,529,814 | 121,544 |
Sector | Health | Health |
52-Week High | $592.85 | $146.65 |
52-Week Low | $332.02 | $0.68 |
Typical Hold Time | 84 Days | 26 Days |
Enterprise Value | $141.54B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.80, and has shown consistent revenue growth, reaching $10.06B in 2025. Analyst consensus is strongly bullish with a $480.78 price target, though the stock faces headwinds from slower procedure growth in some markets.
The outlook for ISRG remains positive due to its dominant position in robotic surgery, expanding international presence, and high recurring revenue. Key risks include competitive pressures, regulatory hurdles, and economic sensitivity affecting procedure volumes. With solid fundamentals and analyst support, the stock offers growth potential, but investors should monitor execution against these risks.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
